ArticleInternational journal of nanomedicine2023
Albumin-Modified Gold Nanoparticles as Novel Radiosensitizers for Enhancing Lung Cancer Radiotherapy.
Article in International journal of nanomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Nanoparticle trends and hotspots in lung cancer diagnosis from 2006-2023: a bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Nanomaterials reshaping cancer radiotherapy: Radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies.Materials today. Bio · 2026Review
- Fuzuloparib enhances radiosensitivity of gain-of-function mutant p53 R273H NSCLC by promoting SLC7A11/GSH/GPX4 axis mediated ferroptosis.NPJ precision oncology · 2026Article
- Gold-incorporated hyaluronic acid nanoparticles enhance ablative radiotherapy efficacy in lung cancer.International journal of pharmaceutics: X · 2026Article
- Precision Multimodal Nanodynamic Therapy for Lung Cancer: From Tumor Microenvironment-Responsive Platforms to Cell-Death Reprogramming and Immune Remodeling.International journal of nanomedicine · 2026Review
- Metal Nanoparticles as Sensitizers in Energy-Based Therapies for Lung Cancer: From Mechanistic Insights to Clinical Translation.International journal of nanomedicine · 2026Review
- Treatment of lung diseasesMaterials today. Bio · 2025Review
- Advances in controlled release drug delivery systems based on nanomaterials in lung cancer therapy: A review.Medicine · 2025Review
- In Vitro and In Vivo Synergetic Radiotherapy with Gold Nanoparticles and Docetaxel for Pancreatic Cancer.Pharmaceutics · 2024Article
- Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment.Molecules (Basel, Switzerland) · 2024Review
- Research Progress of Polysaccharide-Gold Nanocomplexes in Drug Delivery.Pharmaceutics · 2024Review
- Application of nano-radiosensitizers in non-small cell lung cancer.Frontiers in oncology · 2024Review
- Application of nanotechnology in the treatment of hepatocellular carcinoma.Frontiers in pharmacology · 2024Review
- Nano-Assisted Radiotherapy Strategies: New Opportunities for Treatment of Non-Small Cell Lung Cancer.Research (Washington, D.C.) · 2024Review
- Harnessing nanotechnology for cancer treatment.Frontiers in bioengineering and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considering the strong attenuation of photons and the potential to increase the deposition of radiation, high-atomic number nanomaterials are often used as radiosensitizers in cancer radiotherapy, of which gold nanoparticles (GNPs) are widely used. Materials and Methods: We prepared albumin-modified GNPs (Alb-GNPs) and observed their radiosensitizing effects and biotoxicity in human non-small-cell lung carcinoma tumor-bearing mice models. Results: The prepared nanoparticles (Alb-GNPs) demonstrated excellent colloidal stability and biocompatibility at the mean size of 205.06 ± 1.03 nm. Furthermore, clone formation experiments revealed that Alb-GNPs exerted excellent radiosensitization, with a sensitization enhancement ratio (SER) of 1.432, which is higher than X-ray alone. Our in vitro and in vivo data suggested that Alb-GNPs enabled favorable accumulation in tumors, and the combination of Alb-GNPs and radiotherapy exhibited a relatively greater radiosensitizing effect and anti-tumor activity. In addition, no toxicity or abnormal irritating response resulted from the application of Alb-GNPs. Conclusion: Alb-GNPs can be used as an effective radiosensitizer to improve the efficacy of radiotherapy with minimal damage to healthy tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.